Oren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was recently a guest on Benzinga’s All-Access.

Enlivex is a clinical-stage biotechnology company focused on macrophage reprogramming that intends to develop and commercialize a drug pipeline for macrophage reprogramming in solid cancers, sepsis and other indications.

The company’s pioneering cell-based therapy Allocetra™ breaks with old paradigms, offering to effectively treat numerous acute conditions through a radically different clinical approach that centers around macrophage homeostasis. 

Watch the full interview here:

Featured photo by Colton Sturgeon on Unsplash.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.